(Q38347110)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25660101%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

review article

1 reference

title

Review of pharmacoeconomic evaluation of genotype-guided antiplatelet therapy (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25660101%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25660101%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

author name string

Minghuan Jiang

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25660101%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

language of work or name

English

0 references

publication date

7 February 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25660101%20AND%20SRC:MED&resulttype=core&format=json

Expert Opinion on Pharmacotherapy

29 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25660101%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

volume

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25660101%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25660101%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

page(s)

771-779

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25660101%20AND%20SRC:MED&resulttype=core&format=json

Cytochrome p-450 polymorphisms and response to clopidogrel

29 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1013028

Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1013028

The effect of CYP2C19 polymorphism on the pharmacokinetics and pharmacodynamics of clopidogrel: a possible mechanism for clopidogrel resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1013028

Individual variability in the disposition of and response to clopidogrel: pharmacogenomics and beyond.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1013028

Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1013028

Genetic and nongenetic factors influencing the response to clopidogrel

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1013028

Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1013028

Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1013028

Feasibility of a microarray-based point-of-care CYP2C19 genotyping test for predicting clopidogrel on-treatment platelet reactivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1013028

CYP2C19 and PON1 polymorphisms regulating clopidogrel bioactivation in Chinese, Malay and Indian subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1013028

Genetic polymorphism of cytochrome P450 2C19 in Mexican Americans: a cross-ethnic comparative study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1013028

Cytochrome P450 2C19*2 polymorphism and cardiovascular recurrences in patients taking clopidogrel: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1013028

Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1013028

Impact of CYP2C19 variant genotypes on clinical efficacy of antiplatelet treatment with clopidogrel: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1013028

Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1013028

Clinical significance of the cytochrome P450 2C19 genetic polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1013028

Ticagrelor versus clopidogrel in patients with acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1013028

Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1013028

Prasugrel versus clopidogrel in patients with acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1013028

ACCF/AHA Clopidogrel clinical alert: approaches to the FDA "boxed warning": a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the American Heart Association

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1013028

Cost-effectiveness of cytochrome P450 2C19 genotype screening for selection of antiplatelet therapy with clopidogrel or prasugrel

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1013028

Genetic testing in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a cost-effectiveness analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1013028

Ticagrelor versus genotype-driven antiplatelet therapy for secondary prevention after acute coronary syndrome: a cost-effectiveness analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1013028

Cost-effectiveness of using CYP2C19 genotype to guide selection of clopidogrel or ticagrelor in Australia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1013028

CYP2C19 genotype-guided antiplatelet therapy in ST-segment elevation myocardial infarction patients-Rationale and design of the Patient Outcome after primary PCI (POPular) Genetics study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1013028

CYP2C19 genotype has a greater effect on adverse cardiovascular outcomes following percutaneous coronary intervention and in Asian populations treated with clopidogrel: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1013028

Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1013028

Efficacy and safety of intensified antiplatelet therapy on the basis of platelet reactivity testing in patients after percutaneous coronary intervention: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1013028

Prasugrel or double-dose clopidogrel to overcome clopidogrel low-response--the TAILOR (Thrombocytes And IndividuaLization of ORal antiplatelet therapy in percutaneous coronary intervention) randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1013028

Design and anticipated outcomes of the eMERGE-PGx project: a multicenter pilot for preemptive pharmacogenomics in electronic health record systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1013028

A Risk–Benefit Assessment of Prasugrel, Clopidogrel, and Genotype-Guided Therapy in Patients Undergoing Percutaneous Coronary Intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1013028

10.1517/14656566.2015.1013028

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25660101%20AND%20SRC:MED&resulttype=core&format=json

release_55o2c7nn3ndjdnkpfwyaea2ytm

29 February 2020

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/55o2c7nn3ndjdnkpfwyaea2ytm

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25660101%20AND%20SRC:MED&resulttype=core&format=json